The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
Open accessAbstract
Tumor DNA mismatch repair (MMR) deficiency testing is important to the identification of Lynch syndrome and decision making regarding adjuvant chemotherapy in stage II colorectal cancer (CRC) and has become an indispensable test in metastatic tumors due to the high efficacy of immune checkpoint inhibitor (ICI) in deficient MMR (dMMR) tumors. CRCs greatly benefit from this testing as approximately 15% of them are dMMR but only 3% to 5% are at a metastatic stage. MMR status can be determined by two different methods, microsatellite instability (MSI) testing on tumor DNA, and immunohistochemistry of the MMR proteins on tumor tissue. Recent studies have reported a rate of 3% to 10% of discordance between these two tests. Moreover, some reports suggest possible intra- and inter-tumoral heterogeneity of MMR and MSI status. These issues are important to know and to clarify in order to define therapeutic strategy in CRC. This review aims to detail the standard techniques used for the determination of MMR and MSI status, along with their advantages and limits. We review the discordances that may arise between these two tests, tumor heterogeneity of MMR and MSI status, and possible explanations. We also discuss the strategies designed to distinguish sporadic versus germline dMMR/MSI CRC. Finally, we present new and accurate methods aimed at determining MMR/MSI status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“Indeed, patients with dMMR/MSI tumor have drawn a major benefit from immunotherapy, whatever the tumor type, with a rate of disease control reaching 80% and overall survival superior to three years in chemoresistant mCRC cases [10,12,103].”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 4×
“The first reference panel, referred to as the Bethesda panel, consists of two mononucleotide loci (big adenine tract BAT - 25 and BAT-26 ) and three dinucleotide loci ( D2S123 , D5S346 , and D17S250 ) [12].”
InfluentialRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 1×
“Moreover, stage II dMMR/MSI CRCs do not benefit from adjuvant fluoropyrimidine chemotherapy [7,8].”
BackgroundOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 1×
“…trials suggest high efficacy of immune checkpoint inhibitor (ICI) in chemoresistant dMMR/MSI metastatic tumors due to the high tumor mutational burden in these tumors, while the other predictor of response to ICI is the IHC labeling of the PD-L1 protein (programmed death-ligand 1) [12,13].”
Cited by
Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning
Echle, A., Grabsch, H. I., Quirke, P., van den Brandt, P. A., West, N. P., Hutchins, G. G. A., Heij, L. R., Tan, X., Richman, S. D., Krause, J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.021 · Cited by 376
Taieb, J., Svrcek, M., Cohen, R., Basile, D., Tougeron, D., & Phelip, J.-M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.020 · Cited by 326
Self-citationInflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
“The last one, dMMR/MSI, occurs in 15% of CRCs and frequently overlaps with CIMP (about 60–80%) [2,6,7].”
BackgroundMethodSelf-citationMethylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Metadata
- Authors
- Evrard, C., Tachon, G., Randrian, V., Karayan-Tapon, L., & Tougeron, D.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-10-15
- Volume
- 11
- Issue
- 10
- Pages
- 1567
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2981285743
- Cited by
- 181
- References
- 4
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.